Protagenic Therapeutics Posts $1.14 EPS, Announces $8M Cost Cuts & 1-for-14 Reverse Split
Summary
Protagenic Therapeutics (PTIX) filed its 10-Q, reporting $0 revenue and an operating loss of $0.93 million for the quarter, alongside a net income of $2.211 million ($1.14 EPS) driven by non-operating gains. The filing also revealed a significant operational restructuring, including a transition to a virtual model and leadership changes, targeting approximately $8 million in annualized cost savings. Furthermore, the company undertook a 1-for-14 reverse stock split as part of its Nasdaq compliance efforts. For a company with a sub-$1 million market cap, the planned $8 million in cost savings is highly material and critical for its long-term viability, while the reverse stock split addresses immediate listing concerns. Investors will closely monitor the execution of these restructuring efforts and the progress of its prioritized lead candidate, PT00114, into Phase IIa.
At the time of this announcement, PTIX was trading at $0.42 on OTC in the Life Sciences sector, with a market capitalization of approximately $811.8K. The 52-week trading range was $0.25 to $121.13. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Wiseek News.